Postmenopausal women taking anastrozole as a chemopreventive treatment do not have impaired cognitive performance

New results of a sub-study carried out as part of a worldwide breast cancer prevention study (IBIS-II) show that after two years of taking the aromatase inhibitor, anastrozole, postmenopausal women at high risk of breast cancer do not have impaired cognitive performance.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news139832387.html">Postmenopausal women taking anastrozole as a chemopreventive treatment do not have impaired cognitive performance</a></p> <p>New results of a sub-study carried out as part of a worldwide breast cancer prevention study (IBIS-II) show that after two years of taking the aromatase inhibitor, anastrozole, postmenopausal women at high risk of breast cancer do not have impaired cognitive performance.</p>